Journal
LEUKEMIA & LYMPHOMA
Volume 45, Issue 12, Pages 2373-2386Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190400003267
Keywords
myleofibrosis; agnogenic myeloid metaplasia; angiogenesis; anti-antigenesis treatment; myelofibrosis therapy; MPD
Categories
Ask authors/readers for more resources
Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available